Scientists discover mechanism behind cardiac hypertrophy
New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
List view / Grid view
New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
A genetic defect in patients with inflammatory bowel disease (IBD) was found to affect how intestinal epithelial cells maintain a barrier.
Researchers have turned human stem cells into brain cells to create a new model that can predict cognitive decline rate on an individualised level.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
Study reveals that the HSP27 protein plays a role in regulating blood vessel leakage, providing new targets for drugs against sepsis.
Scientists unveiled how a DNA repair protein may prevent Huntington’s disease, presenting a new target in future therapies.
A new model that closely resembles aged lung epithelium in idiopathic pulmonary fibrosis has been developed, possibly leading to treatments.
Researchers have revealed that the protein APOL3 acts as a detergent in human cells, potentially leading to new antibacterial treatments.
SARS-CoV-2 Spike gene mutants may be developed into immunogens for new vaccines against COVID-19, a study in hamsters has shown.
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
Researchers at the University of East Finland have been using skin cells to investigate pathological hallmarks in frontotemporal dementia patients.
A supercomputing method has revealed details of glycan “gates” on the SARS-CoV-2 Spike protein that open to allow virus entry and infection.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.